Article
Mutant PPM1D- and TP53-Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy.
JCO precision oncology - 1 Jan 2022
Singh Abhay, Mencia-Trinchant Nuria, Griffiths Elizabeth A, Altahan Alaa, Swaminathan Mahesh, Gupta Medhavi, Gravina Matthew, Tajammal Rutaba, Faber Mark G, Yan LunBiao, Sinha Eti, Hassane Duane C, Hayes David Neil, Guzman Monica L, Iyer Renuka, Wang Eunice S, Thota Swapna
Abstract excerpt
PURPOSE: Hematologic toxic effects of peptide receptor radionuclide therapy (PRRT) can be permanent. Patients with underlying clonal hematopoiesis (CH) may be more inclined to develop hematologic toxicity after PRRT. However, this association remains understudied. MATERIALS AND METHODS: We evaluated pre- and post-PRRT blood samples of patients with neuroendocrine tumors. After initial screening, 13 cases of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.